REG - GSK PLC - Director/PDMR Shareholding
Today 15:30
For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251222:nRSV4937Ma&default-theme=true
RNS Number : 4937M GSK PLC 22 December 2025
GSK plc (the 'Company')
Transaction notification
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Wendy Becker
b) Position/status Independent Non-Executive Director
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Purchase of 441 Ordinary Shares
c) Price(s) and volume(s) Price(s) Volume(s)
£18.0909 441
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2025-12-19
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Elizabeth (Liz) McKee Anderson
b) Position/status Independent Non-Executive Director
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument American Depositary Shares ('ADSs')
ISIN: US37733W2044
b) Nature of the transaction Purchase of 201 ADSs
c) Price(s) and volume(s) Price(s) Volume(s)
$48.5550 201
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2025-12-19
f) Place of the transaction New York Stock Exchange (XNYS)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Charles Bancroft
b) Position/status Senior Independent Non-Executive Director
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument American Depositary Shares ('ADSs')
ISIN: US37733W2044
b) Nature of the transaction Purchase of 1,577 ADSs
c) Price(s) and volume(s) Price(s) Volume(s)
$48.5550 1,577
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2025-12-19
f) Place of the transaction New York Stock Exchange (XNYS)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Dr Anne Beal
b) Position/status Independent Non-Executive Director
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument American Depositary Shares ('ADSs')
ISIN: US37733W2044
b) Nature of the transaction Purchase of 201 ADSs
c) Price(s) and volume(s) Price(s) Volume(s)
$48.5550 201
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2025-12-19
f) Place of the transaction New York Stock Exchange (XNYS)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Dr Hal Dietz
b) Position/status Independent Non-Executive Director
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument American Depositary Shares ('ADSs')
ISIN: US37733W2044
b) Nature of the transaction Purchase of 201 ADSs
c) Price(s) and volume(s) Price(s) Volume(s)
$48.5550 201
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2025-12-19
f) Place of the transaction New York Stock Exchange (XNYS)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Dr Jeannie Lee
b) Position/status Independent Non-Executive Director
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument American Depositary Shares ('ADSs')
ISIN: US37733W2044
b) Nature of the transaction Purchase of 202 ADSs
c) Price(s) and volume(s) Price(s) Volume(s)
$48.5550 202
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2025-12-19
f) Place of the transaction New York Stock Exchange (XNYS)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Dr Vishal Sikka
b) Position/status Independent Non-Executive Director
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument American Depositary Shares ('ADSs')
ISIN: US37733W2044
b) Nature of the transaction Purchase of 730 ADSs
c) Price(s) and volume(s) Price(s) Volume(s)
$48.5550 730
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2025-12-19
f) Place of the transaction New York Stock Exchange (XNYS)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Lady Susan Symonds
b) Position/status PCA of Sir Jonathan Symonds (Non-Executive Chair)
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Purchase of 1,650 Ordinary Shares
c) Price(s) and volume(s) Price(s) Volume(s)
£18.1046 1,650
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2025-12-22
f) Place of the transaction London Stock Exchange (XLON)
About GSK
GSK is a global biopharma company with a purpose to unite science, technology,
and talent to get ahead of disease together. Find out more at www.gsk.com
(http://www.gsk.com/) .
Registered in England & Wales:
No. 3888792
Registered Office:
79 New Oxford Street
London
WC1A 1DG
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHFEDFFEEISEEE
Copyright 2019 Regulatory News Service, all rights reservedRecent news on GSK
See all newsREG - GSK PLC - Director/PDMR Shareholding
AnnouncementREG - GSK PLC - Transaction in Own Shares
AnnouncementREG - GSK PLC - GSK to lower drug prices and expand access in US
AnnouncementREG - GSK PLC - Transaction in Own Shares
AnnouncementREG - GSK PLC - Transaction in Own Shares
Announcement